| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Ocaratuzumab (anti-CD20)
CAS:1169956-08-4
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13868
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Ocaratuzumab
CAS:1169956-08-4
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Ocaratuzumab
CAS:1169956-08-4
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Ocaratuzumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Ocaratuzumab
CAS:1169956-08-4
Purity:95% PAGE Package:100ug;1mg
|
|
| | Ocaratuzumab Basic information |
| Product Name: | Ocaratuzumab | | Synonyms: | Ocaratuzumab;Research Grade Ocaratuzumab;Ocaratuzumab (anti-CD20) | | CAS: | 1169956-08-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ocaratuzumab Structure]() |
| | Ocaratuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Ocaratuzumab Usage And Synthesis |
| Uses | Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2]. | | References | [1] Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. DOI:10.1158/1078-0432.CCR-11-0850
[2] Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun;6(3):749-55. DOI:10.4161/mabs.28282 |
| | Ocaratuzumab Preparation Products And Raw materials |
|